Condition
ANCA Associated Systemic Vasculitis clinical trials and research
As of November 12, 2026, Find a Trial lists 4 ANCA Associated Systemic Vasculitis clinical trials that are recruiting, in China. By phase: Early Phase 1 (2), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest ANCA Associated Systemic Vasculitis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CD19/BCMA UCART for B cell–related autoimmune diseases | Early Phase 1 | Hangzhou, Zhejiang | Recruiting | May 14, 2026 |
| Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease | Early Phase 1 | Hangzhou, Zhejiang | Recruiting | Apr 2, 2026 |
| TI-0032-III injection for relapsed and refractory B cell–related autoimmune diseases | Phase 1 | Shanghai, Shanghai Municipality | Recruiting | Feb 17, 2026 |
| Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases | Phase 1 | Hangzhou, Zhejiang | Recruiting | Dec 26, 2025 |
All recruiting trials (4)
-
CD19/BCMA UCART for B cell–related autoimmune diseases
This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.
-
Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease
This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.
-
TI-0032-III injection for relapsed and refractory B cell–related autoimmune diseases
This trial tests whether TI-0032-III, an injected therapy that delivers circular RNA instructions for a CD19 CAR to T cells, can help adults with relapsed or treatment‑resistant B cell–related autoimmune diseases such as SLE, Sjögren's, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.
-
Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases
This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.
Related topics
Quick answers
How many ANCA Associated Systemic Vasculitis clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.